Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)
Information source: Seoul National University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Attention Deficit Hyperactivity Disorder
Intervention: Methylphenidate (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Seoul National University Hospital Official(s) and/or principal investigator(s):
Soo-Churl Cho, MD, PhD, Principal Investigator, Affiliation: Seoul National University College of Medicine
Overall contact:
Soo-Churl Cho, MD, PhD, Phone: 82-2-2072-3648, Email: jewook.kang@gmail.com
Summary
The purpose of this study is to determine whether norepinephrine gene polymorphism affect to
treatment response in ADHD
Clinical Details
Official title: Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Clinical Global Impression Scale-Improvement
Secondary outcome: ADHD rating scale
Eligibility
Minimum age: 6 Years.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- diagnosis made by DSM-IV and K-SADS-PL
- IQ > 71
Exclusion Criteria:
- genetic disorder
- history of acquired brain injury
- seizure disorder
- other neurologic disorder
- mental disorder, pervasive developmental disorder
- obsessive-Compulsive disorder
- communication disorder
- learning disorder
Locations and Contacts
Soo-Churl Cho, MD, PhD, Phone: 82-2-2072-3648, Email: jewook.kang@gmail.com
Seoul National University Hospital, Seoul 110-769, Korea, Republic of; Recruiting
Soo-Churl Cho, MD, PhD, Principal Investigator
Additional Information
Starting date: September 2008
Last updated: September 20, 2009
|
